LAUSR

From the *Collins BioMicrosystems Laboratory (CBML), Department of Biomedical Engineering, University of Melbourne, Melbourne, Australia; †CELLINK Life Sciences, Gothenburg, Sweden; ‡School of Biomedical Engineering/FEIT, University of Technology Sydney, Sydney, Australia; and §Sydney Medical School/Faculty of Medicine and Health, University of Sydney, Sydney, Australia. Submitted for consideration November 2020; accepted for publication in revised form December 2020. Disclosure: The authors have no conflicts of interest to report. The event was supported by the School of Biomedical Engineering/ FEIT at the University of Technology Sydney (UTS, Australia), and the several sponsors that supported the meeting: CELLINK, REGEMAT3D, Inventia Life Science, Cytiva, Advanced Solutions, RegenHU, Poietis, Fluicell, Lastek. Significance statement: Bioprinting technology for tissue engineering and regenerative medicine applications holds great promise to recapitulate complex elements of natural tissues and organs. Driving this shift in personalized medical treatment is the need to meet one of the largest modern-day challenges of organ shortage for transplantation. Given its high demand, coupled with limited organ donors, bioprinting is a technology that has the potential to address organ shortage via the production of viable and functional tissue replacements. Although the generation of whole three-dimensional bioprinted organs remains a longer-term goal, bioprinting technology has already demonstrated to be useful in the generation of biomimetic organoids and tissues for research in drug discovery, toxicology screening, and disease modeling. Correspondence: Carmine Gentile, School of Biomedical Engineering/FEIT, Building 11, Level 10, Room 115, 81 Broadway, Ultimo, NSW 2007, Australia. Email: [email protected]. Copyright © ASAIO 2021 DOI: 10.1097/MAT.0000000000001389 Three-Dimensional Bioprinting for Tissue Engineering and Regenerative Medicine in Down Under: 2020 Australian Workshop Summary